Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Accumulated Depreciation (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Accumulated Depreciation for 5 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.4 million, a N/A change, with the full-year FY2024 number at $4.1 million, up 114.94% from a year prior.
  • Accumulated Depreciation was $4.4 million for Q3 2025 at Lyra Therapeutics, up from $4.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $4.7 million in Q3 2022 to a low of $1.9 million in Q4 2023.
  • A 5-year average of $3.7 million and a median of $4.1 million in 2022 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: tumbled 53.98% in 2023, then skyrocketed 114.94% in 2024.
  • Lyra Therapeutics' Accumulated Depreciation stood at $3.9 million in 2021, then rose by 7.61% to $4.2 million in 2022, then crashed by 53.98% to $1.9 million in 2023, then surged by 114.94% to $4.1 million in 2024, then rose by 7.73% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Accumulated Depreciation are $4.4 million (Q3 2025), $4.1 million (Q4 2024), and $2.2 million (Q2 2024).